Morphotek


Morphotek is one of the leading companies in the life science industry that develops novel classes of biological-based products to treat cancer, inflammation and infectious diseases. Since its founding in 2000, Morphotek has made extraordinary progress in discovering and developing monoclonal antibodies (mABs) to treat these diseases and continues to develop additional antibody products using its proprietary technologies. Post-graduate research executed by Morphotek’s President and CEO, Dr. Nicholas Nicolaides, during his studies at Johns Hopkins Medical School was the basis for the company’s inception. It was there that Dr. Nicolaides co-invented the company's legacy technology called morphogenics. Along with the honed applications for applying morphogenics for product development refined by the company’s other co-founders, Dr. Philip Sass and Dr. Luigi Grasso, morphogenics has taken Morphotek an incredible distance in the advancement of novel pharmaceutical products and targets.

Industries

biotechnology
innovation-management
medical

Nr. of Employees

medium (51-250)

Morphotek

Exton, Pennsylvania, United States, North America


Products

RESPECT-H+L

A conjugation technology that allows dual payload delivery with two different mechanisms of action, enabling simultaneous delivery of two cytotoxins to the same cell and in vivo tracking of the ADC.

Eribulin ADC Payload

A payload used in antibody-drug conjugates (ADCs) that exhibits cytotoxic effects on both receptor-positive and neighboring receptor-negative tumor cells, and induces vascular remodeling and mesenchymal-to-epithelial transition in tumors.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.